Efficacy of RAD001 (Everolimus) and Octreotide LAR in Advanced Low- to Intermediate-Grade Neuroendocrine Tumors: Results of a Phase II Study

PURPOSE: Evaluate the activity of everolimus (RAD001) in combination with octreotide long-acting repeatable (LAR) in patients with advanced low- to intermediate-grade neuroendocrine tumors. METHODS: Treatment consisted of RAD001 5 mg/d (30 patients) or 10 mg/d (30 patients) and octreotide LAR 30 mg...

Πλήρης περιγραφή

Αποθηκεύτηκε σε:
Λεπτομέρειες βιβλιογραφικής εγγραφής
Κύριοι συγγραφείς: Yao, James C., Phan, Alexandria T., Chang, David Z., Wolff, Robert A., Hess, Kenneth, Gupta, Sanjay, Jacobs, Carmen, Mares, Jeannette E., Landgraf, Andrea N., Rashid, Asif, Meric-Bernstam, Funda
Μορφή: Artigo
Γλώσσα:Inglês
Έκδοση: American Society of Clinical Oncology 2008
Θέματα:
Gastrointestinal Cancer
Διαθέσιμο Online:https://ncbi.nlm.nih.gov/pmc/articles/PMC2653122/
https://ncbi.nlm.nih.gov/pubmed/18779618
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1200/JCO.2008.16.7858
Ετικέτες: Προσθήκη ετικέτας
Δεν υπάρχουν, Καταχωρήστε ετικέτα πρώτοι!

Παρόμοια τεκμήρια